Work

RNAseq correlative biomarkers IFIT1B and VSTM5 predict progression free survival and clinical benefit in a multi-site Phase I/II trial of Olaparib and Tremelimumab for gBRCAm recurrent ovarian cancer (LBA 11)

Year: 2022

Type: article

Source: Gynecologic Oncology

DOI: 10.1016/s0090-8258(22)01315-4

Authors: Sarah Adams, Carolyn Muller, David O’Malley, Kari Ring, Robert Wenham, Karen Finkelstein, Teresa Rutledge, Elizabeth Lokich, Xavier Paliard, Olivier Rixe, Ichiko Kinjyo, Steven Eberhardt, Ji-Hyun Lee, Phyllis Gimotty

Institutions: University of New Mexico, University of New Mexico Health Sciences Center, The Ohio State University, University of Virginia, Moffitt Cancer Center, Southwest Women's Oncology, Personalis (United States), University of Florida, University of Pennsylvania

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4295226633

FWCI: 0.181

Cites:

Cited by: 2

Related to: 10